Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(60%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_2
2
40%
Ph phase_1
1
20%
Ph phase_3
1
20%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(2)

Detailed Status

Completed2
Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)

Trials by Status

active_not_recruiting120%
completed240%
recruiting240%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_1

Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study

NCT07708714
recruitingphase_3

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

NCT04116502
completedphase_2

SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)

NCT03806452
active_not_recruiting

ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study

NCT04707235
completedphase_2

Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.

NCT05470270

Clinical Trials (5)

Showing 5 of 5 trials
NCT07708714Phase 1

Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study

Recruiting
NCT04116502Phase 3

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

Recruiting
NCT03806452Phase 2

SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)

Completed
NCT04707235

ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study

Active Not Recruiting
NCT05470270Phase 2

Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5